Overcoming oncolytic virus therapy production challenges through collaboration

News
Article

Sponsored Content

Discover how ReciBioPharm’s strategic approach helped to support the rapid delivery of an innovative oncolytic adenovirus therapy for advanced cancer to clinic.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Content
© 2025 MJH Life Sciences

All rights reserved.